PMGC Holdings Inc. (ELAB): Total Liabilities
$5.03M
As of 2025-12-31
$19.83M
As of 2026-06-30
+87.7%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.03M | +115.6% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $2.33M | +71.2% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $1.36M | +79.1% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $760.9K | n/a | 2024-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $5.03M | +115.6% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $5.08M | -14.4% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $2.40M | -83.8% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $69.14M | +0.8% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $140.38M | +6.8% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $1.61M | +19.2% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.69M | -37.6% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $754.4K | +74.3% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $5.00M | -67.6% |
Compare ELAB, VCNX, YARW, SLN side by side · Screen every company in Pharmaceutical Preparations ↗